1. In this randomized controlled trial, apixaban lowered the risk of stroke or systemic embolism significantly more than aspirin in patients with subclinical atrial fibrillation. 2. Apixaban was associated with a higher risk of major bleeding than aspirin. Evidence Rating Level: 1 (Excellent) Study Rundown: Symptomatic atrial fibrillation is a leading cause of stroke and stroke-related […]
The post Apixaban lowers the risk of stroke in subclinical atrial fibrillation first appeared on 2 Minute Medicine.